We are developing our technology in areas of high unmet medical need in (i) debilitating diseases; (ii) where chronic treatment is required to control disease; (iii) and where localised, non-systemic activity promises to improve safety and tolerability. The company also has a wide range of pioneering molecules as potential candidates for a range of gastrointestinal (GI) and ocular inflammatory conditions.

TopiVert’s most advanced drug candidates are:

  • TOP1630 in the treatment of dry eye disease, which recently demonstrated proof of concept in a Phase 1/2a study in the US. 
  • TOP1288 for the treatment of ulcerative colitis (UC) where a Phase 1 study with an oral formulation recently reported strong data ahead of a Phase 2a POC study in UC patients. 
  • TOP1890 oral formulation for the treatment of inflammatory bowel disease is also ready to enter a Phase 1 study (CTA ready)